Everbright Securities anticipates an increase in demand for ...

Everbright Securities anticipates an increase in demand for influenza vaccines in the fall and winter of 2023, boosting the performance of related companies. The Hualan vaccine and Baike Biotech are recommended; the demand for differential diagnosis of respiratory infections will boost the performance of related companies and recommend Antu Biotech; the peak demand for Q4 cold medicines is expected to expedite the clearance of social inventories; Eling Pharmaceutical, Kangyuan Pharmaceutical, etc. are recommended.